Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Authors

  • Danielle Rogner Department of Dermatology, Technical University of Munich, DE-80802 Munich, Germany
  • Tilo Biedermann
  • Felix Lauffer

DOI:

https://doi.org/10.2340/actadv.v102.1088

Keywords:

atopic dermatitis, JAK-inhibition, Baricitinib

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.

https://doi.org/10.1111/jdv.15634

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.

https://doi.org/10.1111/jdv.14888

Hajar T, Hanifin JM, Gontijo JRV. New and developing therapies for atopic dermatitis. An Bras Dermatol 2018; 93: 104-107.

https://doi.org/10.1590/abd1806-4841.20187682

Blauvelt A, Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol 2019; 181: 196-197.

https://doi.org/10.1111/bjd.17703

Lauffer F, Ring J. Target-oriented therapy: emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 2016; 21: 81-89.

https://doi.org/10.1517/14728214.2016.1146681

Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 2020; 21: 119-131.

https://doi.org/10.1007/s40257-019-00478-y

Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018; 78: S53-S62.

https://doi.org/10.1016/j.jaad.2017.12.019

Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat 2020 Nov 22. [Epub ahad of print].

https://doi.org/10.1080/09546634.2020.1839008

Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333-1343.

https://doi.org/10.1001/jamadermatol.2020.3260

Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med 2020; 3: 67.

https://doi.org/10.1038/s41746-020-0277-8

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.

https://doi.org/10.1034/j.1600-0625.2001.100102.x

Singh RK, Finlay AY. Dermatology Life Quality Index use in skin disease guidelines and registries worldwide. J Eur Acad Dermatol Venereol 2020; 34: e822-e824.

https://doi.org/10.1111/jdv.16701

Oranje AP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol 2011; 41: 149-155.

https://doi.org/10.1159/000323308

Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012; 92: 497-501.

https://doi.org/10.2340/00015555-1265

Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.

https://doi.org/10.1111/bjd.18898

Downloads

Published

2022-03-22

How to Cite

Rogner, D., Biedermann, T., & Lauffer, F. (2022). Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience. Acta Dermato-Venereologica, 102, adv00677. https://doi.org/10.2340/actadv.v102.1088

Issue

Section

Short Communication

Categories